Background:
A varying response to cholinesterase inhibitor (ChEI) treatment has been reported
among patients with Alzheimer’s disease (AD). Whether the individual-specific response directly
affects time to nursing home placement (NHP) was not investigated.
Objective:
We examined the relationship between the 6-month response to ChEI and institutionalization.
Methods:
In a prospective, observational, multicenter study, 881 outpatients with a clinical AD diagnosis
and a Mini-Mental State Examination score of 10-26 at the start of ChEI therapy (baseline) were included.
The participants were evaluated using cognitive, global, and activities of daily living (ADL)
scales at baseline and semiannually over 3 years. The date of NHP was recorded.
Results:
During the study, 213 patients (24%) were admitted to nursing homes. The mean ± standard
deviation time from baseline (AD diagnosis) to NHP was 20.8 ± 9.3 months. After 6 months of ChEI
treatment, the improved/unchanged individuals had longer time to NHP than those who worsened. The
prolonged time to NHP was 3 months for cognitive response (P=0.022), 4 months for global response
(P=0.004), 6 months for basic ADL response (P<0.001), and 8 months for response in all three scales
(P<0.001). No differences were detected between the improved and unchanged groups in any scales.
Conclusion:
Patients who exhibit a positive short-term response to ChEI can expect to stay in their own
home for 3-8 months longer. These findings underline the importance of a comprehensive clinical examination
including various assessment scales to evaluate treatment response and provide a more accurate
prognosis.
P3-350: Cholinesterase inhibitor (ChEI) treatment benefits in mild compared to moderate Alzheimer's disease
